Skip to content
Catalyst

PapersPMID:17987126

Effects of a flaxseed-derived lignan supplement in type 2 diabetic patients: a randomized, double-blind, cross-over trial.

PloS one2007The record ↗

findings
2
compound
1
endpoints
2
  1. Finding, limited evidenceno difference foundHOMA-IR
  2. Finding, limited evidenceno difference foundFasting blood glucose
Study, every finding
crossover · 3 months
Dose studied, every finding
three capsules (0.6 g each) daily, 360 mg isolated flaxseed lignan per day, 12 weeks
Population, every finding
68 adults with type 2 diabetes and mild hypercholesterolaemia (LDL-C 2.9 mmol/L or above), 60 on oral hypoglycaemic agents; 12-week treatment periods separated by an 8-week washout

No finding here moved its endpoint.

  • “Compared with the values after 12-week placebo treatment, HbA1c was significantly reduced with lignan supplementation, whereas changes in HOMA-IR, fasting glucose and insulin concentrations were not significantly different between the two treatments.”

Study record

Design
crossover trial
Species
human
Population
Type 2 diabetic patients aged 50-79 years with LDL-C of at least 2.9 mmol/L, Shanghai
Participants
73
Comparator
placebo
Duration
84 days
Endpoints measured
23